//

GlaxoSmithKline PLC

Posted Mon, 09/14/2009 - 12:39 by Zefu

GlaxoSmithKline PLC

980 Great West Road, Brentford
Middlesex, EN TW8 9
UK
Phone: (888) 825-5249
Fax:
Web Site: http://www.gsk.com/

A. Company Profile

GlaxoSmithKline (NYSE:GSK) is one of the world's leading pharmaceutical companies. The company's product portfolio includes innovative treatments across a wide range of therapeutic areas. There are extensive discovery and development programs in the field of oncology at GlaxoSmithKline

B. Products

Product Pipelines
Product Indication Clinical Status
572016 Bladder, breast, gastric, head and neck, and lung cancers Phase III
BEXXAR Non-Hodgkin's lymphoma Market
  Melanoma Phase III
  Colorectal cancer Phase II
  Lymphoma and pancreatic cancer Phase I
Cervarix Cervical cancer Phase III
Elacridar Various tumors Phase I
Ethynylcytidine Various tumors Phase II
Hycamtin Small cell lung cancer (2nd line) Market
  Non-small cell lung cancer (2nd line), ovarian cancer (1st line), small cell lung cancer (1st line), and small cell lung cancer (2nd line) - oral formulation Phase III
Lapatinib Breast cancer Phase III
Navelbine Breast and non small cell lung cancers Phase III
Nelarabine Acute lymphoblastic leukaemia and lymphomas Phase III

1. 572016

572016 is an ErbB-1 (EGFR) and ErbB-2 (HER2/NEU) dual kinase inhibitors. These two receptors have been implicated in the growth of various tumor types, and often are associated with a poor prognosis.

2. Bexxar

The Bexxar therapeutic regimen (Tositumomab and Iodine I 131 Tositumomab) is approved by the FDA for the treatment of patients with CD20 positive, follicular, non-Hodgkin's lymphoma, with and without transformation, whose disease is refractory to Rituximab and has relapsed following chemotherapy.

3. Elacridar

Elacridar (GF120918), oral bioenhancer, is in the latest generation of multi-drug resistance-interacting compounds that specifically target the membrane-bound P-glycoprotein efflux pump.

4. Ethynylcytidine

Ethynylcytidine is a selective RNA polymerase inhibitor.

5. Hycamtin

Hycamtin (Topetecan) is a semi-synthetic derivative of camptothecin and is an anti-tumor drug with topoisomerase I inhibitory activity.

6. Lapatinib

Laptinib is a blocker of tumor growth receptor and tumor-promoting protein.

7. Navelbine

Navelbine, a vinca alkaloid, is a microtubule inhibitor. It interferes with the growth of cancer cells and slows their growth and spread in the body.

8. Nelarabine

Nelarabine is a novel water soluble prodrug of ara-G with T- cell selectivity. It is a nucleoside analogue that is rapidly converted to its corresponding arabinosylguanine nucleotide triphosphate (araGTP), resulting in inhibition of DNA synthesis and cytotoxity.